Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

Citation

Published Version
doi:10.2147/OPTH.S81523

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856858

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

Laurence S Lim1,2
Wei Yan Ng2
Ranjana Mathur3
Doric Wong2
Edmund YM Wong2
Ian Yeo2
Chui Ming Gemmy Cheung2
Shu Yen Lee2
Tien Yin Wong2
Thanos D Papakostas1
Leo A Kim1

1Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA;
2Vitreoretinal Department, Singapore National Eye Centre, Singapore

Background: The purpose of this study was to determine if eyes with diabetic macular edema (DME) unresponsive to ranibizumab or bevacizumab would benefit from conversion to aflibercept.

Methods: This study was conducted as a retrospective chart review of subjects with DME unresponsive to ranibizumab and/or bevacizumab and subsequently converted to aflibercept.

Results: In total, 21 eyes from 19 subjects of mean age 62±15 years were included. The majority of subjects were male (63%). The median number of ranibizumab or bevacizumab injections before switching to aflibercept was six, and the median number of aflibercept injections after switching was three. Median follow-up was 5 months after the switch. Mean central foveal thickness (CFT) was 453.52±143.39 mm immediately prior to the switch. Morphologically, intraretinal cysts were present in all cases. Mean CFT after the first injection decreased significantly to 362.57±92.82 mm (Wilcoxon signed-rank test; P<0.001). At the end of follow-up, the mean CFT was 324.17±98.76 mm (P<0.001). Mean visual acuity was 0.42±0.23 logMAR just prior to the switch, 0.39±0.31 logMAR after one aflibercept injection, and 0.37±0.22 logMAR at the end of follow-up. The final visual acuity was significantly better than visual acuity before the switch (P=0.04).

Conclusion: Eyes with DME unresponsive to multiple ranibizumab/bevacizumab injections demonstrate anatomical and visual improvement on conversion to aflibercept.

Keywords: diabetic retinopathy, macular edema, aflibercept, bevacizumab, ranibizumab

Introduction

Diabetic retinopathy is a major cause of visual loss worldwide, with vision-threatening diabetic retinopathy being present in 10% of people with diabetes. Diabetic macular edema (DME) is the main cause of visual impairment in diabetic retinopathy, and there is ample evidence for the role of vascular endothelial growth factor (VEGF) in the pathogenesis of DME.1–6 Several large clinical trials have established the important role of the anti-VEGF agents, ranibizumab and bevacizumab, in the treatment of DME.7–12

Aflibercept is a novel anti-VEGF agent composed of the VEGF-binding portions of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. Aflibercept functions as a soluble decoy receptor. The DA VINCI, VISTA, and VIVID studies have established that treatment with aflibercept yields greater visual gains than macular laser treatment, and the drug has since received US Food and Drug Administration approval for this indication.13–15 A recent trial has also demonstrated that aflibercept is superior to ranibizumab or bevacizumab for eyes with DME and poorer presenting acuity.
Currently, many patients who have received ranibizumab or bevacizumab for the treatment of DME and who have failed to respond to these drugs are being switched to aflibercept. Differences in the pharmacodynamics of aflibercept compared with ranibizumab or bevacizumab have been the basis of this strategy. Unlike ranibizumab, aflibercept binds VEGF with much greater affinity and also binds placental growth factor. Some patients may also be switched to aflibercept due to its reportedly longer duration of action. There are currently few data on the outcomes following this therapeutic switch. Retrospective data from subjects receiving this treatment for age-related macular degeneration have suggested that anatomical improvement with less significant visual improvement can be expected.

The aim of this study was to evaluate the short-term outcomes following conversion from ranibizumab or bevacizumab therapy to aflibercept for the treatment of refractory DME.

Materials and methods
This was a retrospective series of patients treated at two tertiary eye care centers, ie, Singapore National Eye Centre and Massachusetts Eye and Ear Infirmary. Subjects were identified from electronic medical records using the appropriate International Classification of Diseases and billing codes. Subjects were included if they had been treated for DME with ranibizumab and/or bevacizumab and were subsequently converted to aflibercept between September 2012 and September 2014. Exclusion criteria included other visually significant ocular pathology and complications of diabetic retinopathy (eg, tractional retinal detachment, vitreous hemorrhage), loss to follow-up, fewer than three ranibizumab and/or bevacizumab injections prior to conversion to aflibercept, and incomplete imaging or clinical data.

Patient demographics, systemic comorbidities, and patients’ diabetes control (HbA1c levels) were recorded. The main outcomes of note were the best-corrected visual acuity, which was recorded as Snellen visual acuity and converted to logMAR equivalents for analysis, and the anatomical changes as documented on optical coherence tomography. Spectral-domain optical coherence tomography was performed using the Cirrus (Carl Zeiss Meditec, Dublin, CA, USA) or Spectralis (Heidelberg Engineering, Heidelberg, Germany) platforms. The main optical coherence tomography measures of note were central foveal thickness (CFT) as well as the presence of intraretinal or subretinal fluid on the tomogram. The CFT values were automatically generated by the imaging software and used in the analyses after the tomograms had been reviewed for segmentation errors. In cases where segmentation errors were seen, the CFT was manually measured from the tomogram showing the greatest foveal elevation. Intraretinal or subretinal fluid was classified dichotomously as either present or absent, with cases in which only trace fluid was seen (very fine intraretinal cysts or very thin slivers of subretinal fluid) being classified as absent.

The study complied with the Health Insurance Portability and Accountability Act of 1996 and was performed in accordance with the tenets of the Declaration of Helsinki as revised in 1989. This was an observational, retrospective, noninterventional study, and approval and waiver of consent were obtained from the institutional review boards of both institutions.

Results
In total, 21 eyes were included from 19 subjects. Their mean age was 62±15 years and most were male (63%). The mean HbA1c was 6.9±0.7%. Of the 21 eyes, nine had received panretinal photocoagulation. Fifteen eyes had received focal laser before the switch and none after. The median number of ranibizumab or bevacizumab injections before switching to aflibercept was six, and the median number of aflibercept injections after switching was three. Median follow-up was 5 months after the switch.

The mean interval between bevacizumab/ranibizumab injections prior to the switch was 2.4±2.2 months and the interval between aflibercept injections was 2.4±2.2 months (P=0.92). The mean CFT at presentation was 385.65±15.16 and 431.18±147.79 µm immediately prior to the switch (P=0.17). Morphologically, intraretinal cysts were present in all cases. The mean CFT after the first aflibercept injection reduced significantly to 362.57±92.82 mm (Wilcoxon signed-rank test; P<0.001). At the end of follow-up, the mean CFT was 324.17±98.76 mm (P<0.001, Figure 1). The mean visual acuity was 0.42±0.23 logMAR just prior to the switch, 0.39±0.31 logMAR after one aflibercept injection, and 0.37±0.22 logMAR at the end of follow-up (Figure 2). The final visual acuity was significantly better compared with the visual acuity before the switch (P=0.04). Three of the 21 eyes (14%) had complete resolution of intraretinal cysts at the end of follow-up.

A representative case is shown in Figure 3. A 78-year-old woman had long-standing diabetes with a recent HbA1c of 7.5%. After four bevacizumab injections, the right eye had persistent center-involving DME with a CFT of 516 mm and large cystoid spaces (Figure 3A). The CFT reduced to 455 mm after one aflibercept injection (Figure 3B). After six aflibercept injections, the CFT was 357 mm and the cystoid spaces had resolved, although a hyperreflective clump of hard exudates was still seen with disruption of the ellipsoid zone (Figure 3C).
Discussion

In the course of DME treatment, physicians may choose to switch between anti-VEGF agents for various reasons. Clinical reasons include the theoretically greater affinity of aflibercept for VEGF as well as the fact that it also binds to and neutralizes placental growth factor. These pharmacodynamic differences may be particularly useful in situations unresponsive to ranibizumab or bevacizumab. In addition, physicians may choose to switch a patient to aflibercept to take advantage of its reportedly longer duration of action.

Anti-VEGF treatment with bevacizumab or ranibizumab has been clearly shown to be effective and superior to laser for the treatment of DME involving the foveal center. Pegaptanib was the first anti-VEGF agent shown to be effective in the management of DME. Several large trials, including the READ-2 study, RESOLVE, and the Diabetic Retinopathy Clinical Research (DRCR) Network group studies, have shown anti-VEGF treatment with bevacizumab or ranibizumab to be superior to laser alone. Despite these encouraging results with anti-VEGF agents, some cases either do not respond at all to ranibizumab or bevacizumab, or demonstrate an initial response to treatment followed by subsequent nonresponse to further treatment or during disease reactivation. Various mechanisms may underlie this loss of therapeutic effect. Pharmacodynamic mechanisms include increased VEGF expression from inflammatory cells and upregulation of VEGF receptors, while pharmacokinetic tolerance represents an immune response to the anti-VEGF antibodies injected leading to rapid clearance. In these cases, other agents may be used to suppress VEGF. For example, an intravitreal dexamethasone implant (Ozurdex®) has been shown to be effective in eyes unresponsive to treatment with bevacizumab or ranibizumab.

More recently, aflibercept has likewise been shown to be effective in the treatment of center-involving DME, producing results comparable with those for ranibizumab and bevacizumab. The DA VINCI trial evaluated different doses and dosing regimens of aflibercept with laser photocoagulation in eyes with DME. Patients with center-involving DME were assigned to either laser treatment or one of four aflibercept dosing groups. At 24 weeks, all the aflibercept groups had greater visual gains than the laser group, with mean improvements in acuity ranging from 8.5 to 11.4 letters for the aflibercept groups compared with 2.5 letters for the laser group. The differences were even more distinct at 52 weeks, with letter mean gains of 9.7–12.0 in the aflibercept groups versus a mean letter loss of 1.3 in the laser group.

---

**Figure 1** Change in mean central foveal thickness (µm).

**Figure 2** Change in mean logMAR visual acuity.

**Figure 3** This 78-year-old woman had long-standing diabetes with a recent HbA1c of 7.5%.

**Notes:**

(A) After four bevacizumab injections, the right eye had persistent center-involving diabetic macular edema with a CFT of 516 mm and large cystoid spaces.

(B) The CFT decreased to 455 mm after one aflibercept injection.

(C) After six aflibercept injections, the CFT was 357 mm and the cystoid spaces had resolved, although a hyperreflective clump of hard exudates was still seen with ellipsoid zone disruption.

**Abbreviations:** CFT, central foveal thickness; HbA1c, glycated hemoglobin.
All the aflibercept groups also demonstrated significantly greater reductions in CFT compared with the laser group. The VISTA and VIVID trials have shown similar results, with aflibercept being superior to laser.18 The DRCR Network has recently published the results of a seminal trial comparing the three anti-VEGF agents for DME.19 Over 1 year, eyes with presenting visual acuity worse than approximately 20/50 experienced greater visual improvement on treatment with aflibercept compared with bevacizumab or ranibizumab, with mean letter gains of 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab. These studies suggest that cases unresponsive to ranibizumab and bevacizumab may respond instead to aflibercept.

To our knowledge, there are limited data on the results of switching to aflibercept after treatment with ranibizumab or bevacizumab for DME. Our study is limited by its small sample size and the inherent limitations of a retrospective report. Different optical coherence tomography platforms were also used, although each patient was always imaged with the same platform for follow-up scans. Nevertheless, significant visual and anatomical improvement with CFT reduction were seen after just one injection and at the end of follow-up. Our findings are consistent with those of the DRCR Network study,19 and support the notion that aflibercept may be more effective than ranibizumab or bevacizumab for more resistant cases. However, complete elimination of chronic cystoid spaces is difficult, and longer follow-up is needed to determine the effects of these lesions on vision.

Conclusion

Patients with center-involving DME who are unresponsive to ranibizumab or bevacizumab demonstrate anatomical and visual improvements after conversion to aflibercept. While aflibercept injections are much more costly than bevacizumab, the improvement that can be anticipated in these challenging cases suggests that making the switch is justifiable. Further study is warranted to determine if injection intervals can be extended with aflibercept.

Disclosure

The authors report no conflicts of interest in this work.

References